GA2LEN ANACARE consensus statement: Potential of omalizumab in food allergy management

GA2LEN ANACARE consensus statement: Potential of omalizumab in food allergy management

Abstract Immunoglobulin E (IgE)‐mediated food allergies are the most common type of food allergy, often causing rapid symptoms after exposure to allergens posing a serious health risk and a high impact on patient's and caregiver's quality of life. Omalizumab, a humanized anti‐IgE monoclona...

Full description

Bibliographic Details
Main Authors: Torsten Zuberbier, Antonella Muraro, Ulugbek Nurmatov, Stefania Arasi, Katarina Stevanovic, Aikaterini Anagnostou, Roberta Bonaguro, Sharon Chinthrajah, Gideon Lack, Alessandro Fiocchi, Thuy‐My Le, Paul Turner, Montserrat Alvaro Lozano, Elizabeth Angier, Simona Barni, Phillippe Bégin, Barbara Ballmer‐Weber, Victoria Cardona, Carsten Bindslev‐Jensen, Antonella Cianferoni, Nicolette deJong, Debra deSilva, Antoine Deschildre, Audrey Dunn Galvin, Motohiro Ebisawa, David M. Fleischer, Jennifer Gerdts, Mattia Giovannini, Josefine Gradman, Susanne Halken, Syed Hasan Arshad, Ekaterina Khaleva, Susanne Lau, Richard Loh, Mika J. Mäkelä, Mary Jane Marchisotto, Laura Morandini, Charlotte G. Mortz, Caroline Nilsson, Anna Nowak‐Wegrzyn, Marcia Podestà, Lars K. Poulsen, Graham Roberts, Pablo Rodríguez del Río, Hugh A. Sampson, Angel Sánchez, Sabine Schnadt, Peter K. Smith, Hania Szajewska, Natasa Teovska Mitrevska, Alice Toniolo, Carina Venter, Amena Warner, Gary W. K. Wong, Robert Wood, Margitta Worm
Format: Article
Language:English
Published: Wiley 2024-11-01
Series:Clinical and Translational Allergy
Subjects:
anaphylaxis
desensitization
food allergy
immunoglobulin E
omalizumab
Online Access:https://doi.org/10.1002/clt2.70002

Internet

https://doi.org/10.1002/clt2.70002

Similar Items